NASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free SAVA Stock Alerts $19.72 -0.17 (-0.85%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$19.57▼$20.9250-Day Range$18.81▼$26.1152-Week Range$12.32▼$32.10Volume688,210 shsAverage Volume566,600 shsMarket Capitalization$946.17 millionP/E RatioN/ADividend YieldN/APrice Target$131.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cassava Sciences alerts: Email Address Cassava Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside564.3% Upside$131.00 Price TargetShort InterestBearish25.93% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.86) to $1.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.16 out of 5 starsMedical Sector320th out of 914 stocksPharmaceutical Preparations Industry145th out of 429 stocks 3.5 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted25.93% of the outstanding shares of Cassava Sciences have been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 2.81%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 2.2 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cassava Sciences this week, compared to 5 articles on an average week.Search Interest34 people have searched for SAVA on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($1.86) to $1.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cassava Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Cassava Sciences Stock (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Stock News HeadlinesJune 4, 2024 | seekingalpha.comAll Eyes On Simufilam: Cassava Sciences' Make-Or-Break MomentMay 29, 2024 | msn.comGPT's inaccuracies in agriculture could lead to crop losses and food crisesMay 17, 2024 | benzinga.comPeering Into Cassava Sciences's Recent Short InterestMay 10, 2024 | markets.businessinsider.comSAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024May 10, 2024 | msn.comCassava swings to Q1 profit as more patients finish simufilam phase 3 trialsMay 10, 2024 | msn.comCassava Sciences (NASDAQ:SAVA): Cracking Alzheimer’s or Succumbing to Short Sellers?May 10, 2024 | globenewswire.comCassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of SimufilamMay 10, 2024 | seekingalpha.comAnnovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's BoxMay 8, 2024 | msn.comCassava Sciences raises over $125M from warrant distributionMay 8, 2024 | globenewswire.comCassava Sciences Announces Over $125 Million Raised from Warrant DistributionMay 1, 2024 | msn.comCassava Sciences files for mixed shelf offeringMay 1, 2024 | msn.com27 Best Things to Do in San Francisco, CaliforniaMay 1, 2024 | msn.comCassava: The perilous past and promising future of a toxic but nourishing cropMay 1, 2024 | globenewswire.comTomorrow is Last Day to Trade SAVAW Warrants on NASDAQApril 30, 2024 | msn.comAATF launches mechanised cassava processing plant in OyoApril 30, 2024 | investorplace.comStock Market Crash Warning: Don't Get Caught Holding These 3 Biotech StocksApril 28, 2024 | msn.comExpensive sanitary pads: Agony of girls using clothes for menstruationApril 27, 2024 | msn.comCenterpiece program has crashed and burnedApril 27, 2024 | msn.comHow to grow cocoyamsApril 26, 2024 | msn.comExamining the impact of gene-based breeding on agriculture and medicineApril 26, 2024 | msn.comAdvancing cassava brown streak disease resistanceApril 20, 2024 | msn.comHow Western food imports are fuelling obesity in Pacific nationsApril 19, 2024 | finance.yahoo.comCassava Sciences, Inc. (SAVA)April 15, 2024 | globenewswire.comRedemption Date Announced for WarrantsApril 5, 2024 | bizjournals.comAg nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employeesSee More Headlines Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/15/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$131.00 High Stock Price Target$131.00 Low Stock Price Target$131.00 Potential Upside/Downside+564.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.08% Return on Assets-53.72% Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book6.05Miscellaneous Outstanding Shares47,980,000Free Float43,658,000Market Cap$946.17 million OptionableOptionable Beta-0.50 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Remi Barbier (Age 64)Founder, Chairman, President & CEO Comp: $1.2MMr. Eric J. Schoen (Age 56)Chief Financial Officer Comp: $460kMr. R. Christopher Cook (Age 60)Senior VP, Company Secretary & General Counsel Comp: $425kDr. James W. Kupiec M.D. (Age 71)Chief Medical Officer Comp: $435kDr. George Thornton Ph.D.Senior Vice President of TechnologyMr. Michael ZamlootSenior Vice President of Technical OperationsDr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsDr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceMore ExecutivesKey CompetitorsCollegium PharmaceuticalNASDAQ:COLLVerrica PharmaceuticalsNASDAQ:VRCANature's Sunshine ProductsNASDAQ:NATRscPharmaceuticalsNASDAQ:SCPHVerastemNASDAQ:VSTMView All CompetitorsInsiders & InstitutionsWalleye Trading LLCBought 34,500 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 1,926 shares on 5/16/2024Ownership: 0.084%Price T Rowe Associates Inc. MDBought 1,456 shares on 5/15/2024Ownership: 0.065%CANADA LIFE ASSURANCE CoBought 5,594 shares on 5/14/2024Ownership: 0.022%EntryPoint Capital LLCBought 2,127 shares on 5/14/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions SAVA Stock Analysis - Frequently Asked Questions Should I buy or sell Cassava Sciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SAVA shares. View SAVA analyst ratings or view top-rated stocks. What is Cassava Sciences' stock price target for 2024? 1 brokerages have issued 1 year price targets for Cassava Sciences' stock. Their SAVA share price targets range from $131.00 to $131.00. On average, they predict the company's share price to reach $131.00 in the next twelve months. This suggests a possible upside of 564.3% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts. How have SAVA shares performed in 2024? Cassava Sciences' stock was trading at $22.51 on January 1st, 2024. Since then, SAVA shares have decreased by 12.4% and is now trading at $19.72. View the best growth stocks for 2024 here. When is Cassava Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our SAVA earnings forecast. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) posted its earnings results on Friday, May, 10th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.90. What ETFs hold Cassava Sciences' stock? ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares Neuroscience and Healthcare ETF (IBRN).iShares U.S. Pharmaceuticals ETF (IHE). When did Cassava Sciences' stock split? Cassava Sciences's stock split on the morning of Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were issued to shareholders after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA). Who are Cassava Sciences' major shareholders? Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.45%), Gallacher Capital Management LLC (1.35%), Walleye Trading LLC (0.00%), Clear Creek Financial Management LLC (0.32%), Susquehanna Portfolio Strategies LLC (0.24%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SAVA) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.